Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar

Hikma Holds Exclusive Rights To Commercialize The Ustekinumab Product In The US

Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis. 

Ustekinumab vial
Ustekinumab is used to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis • Source: Shutterstock

Chinese biosimilar developer Bio-Thera Solutions Ltd. has announced positive results from its Phase III study into its asset BAT2206, a proposed biosimilar to Stelara (ustekinumab). The results demonstrated that BAT2206 is highly similar to Stelara in patients with moderate to severe plaque psoriasis.

The global, multi-center, randomized, double-blind, parallel-arm Phase III study compared the efficacy, safety, immunogenicity and pharmacokinetics of BAT2206 and Stelara...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.